Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Immunogenicity of H5N1 Adjuvanted, Inactivated, Split-Virion Pandemic Influenza Vaccine in Healthy Adults

NCT00457509 is registered in ClinicalTrials.gov with Sanofi Pasteur, a Sanofi Company as lead sponsor.

NCT NCT00457509
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00457509 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Immunogenicity of H5N1 Adjuvanted, Inactivated, Split-Virion Pandemic Influenza Vaccine in Healthy Adults
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Phase
Phase 1
Overall status
Completed
Start date
January 31, 2007
Completion date
September 30, 2010
Enrollment
251 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

influenza a virus infection, orthomyxoviridae infections, pandemic influenza